![[2602.15019] Hunt Globally: Deep Research AI Agents for Drug Asset Scouting in Investing, Business Development, and Search & Evaluation](https://arxiv.org/static/browse/0.3.4/images/arxiv-logo-fb.png){kind=logo}
[2602.15019] Hunt Globally: Deep Research AI Agents for Drug Asset Scouting in Investing, Business Development, and Search & Evaluation
Summary
The paper discusses the development of a Deep Research AI agent, Bioptic Agent, designed for drug asset scouting, particularly in non-U.S. markets. It highlights the need for improved AI capabilities in identifying under-the-radar drug candidates and presents a benchmarking me...
Why It Matters
As global drug development increasingly shifts outside the U.S., investors and business development teams face significant risks if they fail to identify emerging assets. This research addresses the limitations of current AI tools in multilingual and heterogeneous environments, proposing a solution that could enhance scouting efficiency and accuracy, ultimately impacting investment strategies and drug discovery.
Key Takeaways
- The majority of new drug assets are now originating outside the U.S., particularly in China.
- Current Deep Research AI agents struggle with high-recall discovery across diverse, multilingual sources.
- The Bioptic Agent outperforms existing models in drug asset scouting, achieving a significant F1 score.
- A benchmarking methodology is proposed to evaluate AI performance in drug asset scouting.
- Increased computational resources lead to improved AI performance in scouting tasks.
Computer Science > Artificial Intelligence arXiv:2602.15019 (cs) [Submitted on 16 Feb 2026] Title:Hunt Globally: Deep Research AI Agents for Drug Asset Scouting in Investing, Business Development, and Search & Evaluation Authors:Alisa Vinogradova, Vlad Vinogradov, Luba Greenwood, Ilya Yasny, Dmitry Kobyzev, Shoman Kasbekar, Kong Nguyen, Dmitrii Radkevich, Roman Doronin, Andrey Doronichev View a PDF of the paper titled Hunt Globally: Deep Research AI Agents for Drug Asset Scouting in Investing, Business Development, and Search & Evaluation, by Alisa Vinogradova and 9 other authors View PDF HTML (experimental) Abstract:Bio-pharmaceutical innovation has shifted: many new drug assets now originate outside the United States and are disclosed primarily via regional, non-English channels. Recent data suggests >85% of patent filings originate outside the U.S., with China accounting for nearly half of the global total; a growing share of scholarly output is also non-U.S. Industry estimates put China at ~30% of global drug development, spanning 1,200+ novel candidates. In this high-stakes environment, failing to surface "under-the-radar" assets creates multi-billion-dollar risk for investors and business development teams, making asset scouting a coverage-critical competition where speed and completeness drive value. Yet today's Deep Research AI agents still lag human experts in achieving high-recall discovery across heterogeneous, multilingual sources without hallucinations. We pro...
